Management of Symptomatic Bradycardia (Heart Rate <50 bpm)
For symptomatic bradycardia with signs of poor perfusion (altered mental status, chest pain, heart failure, hypotension, or shock), immediately administer atropine 0.5 mg IV every 3-5 minutes up to 3 mg total while preparing for transcutaneous pacing. 1
Initial Assessment and Stabilization
Determine if bradycardia is causing the symptoms by identifying signs of poor perfusion including acute altered mental status, ischemic chest discomfort, acute heart failure, hypotension, or other signs of shock. 1
Immediate Actions (Do Not Delay Treatment):
Assess oxygenation status by evaluating work of breathing (tachypnea, intercostal retractions, suprasternal retractions, paradoxical abdominal breathing) and pulse oximetry; provide supplemental oxygen if hypoxemic. 1
Establish IV access, attach cardiac monitor, and measure blood pressure. 1
Obtain 12-lead ECG to identify the specific rhythm (sinus bradycardia, AV block type, etc.), but do not delay treatment to obtain it. 1
Identify and treat reversible causes including hypoxemia, medications (beta-blockers, calcium channel blockers, digoxin), electrolyte disturbances (hyperkalemia), and acute myocardial infarction. 1, 2
Pharmacologic Management
First-Line: Atropine
Atropine 0.5-1 mg IV bolus is the first-line drug for acute symptomatic bradycardia, repeated every 3-5 minutes to a maximum total dose of 3 mg. 1
Critical caveat: Doses <0.5 mg may paradoxically slow heart rate further through a parasympathomimetic response. 1
Atropine is most effective for:
- Sinus bradycardia with cholinergic-mediated slowing 1
- AV block at the AV node level (Mobitz type I) 1
- Bradycardia occurring within 6 hours of acute MI onset 1
Atropine is INEFFECTIVE or HARMFUL in:
- Post-heart transplant patients without autonomic reinnervation (Class III: Harm) 1
- Mobitz type II or third-degree AV block with wide QRS escape rhythm (block is below AV node in His-Purkinje system) 1
Second-Line: Chronotropic Agents (If Atropine Fails)
For patients at low likelihood of coronary ischemia, consider beta-agonists: 1
Dopamine: 5-20 mcg/kg/min IV, starting at 5 mcg/kg/min and increasing by 5 mcg/kg/min every 2 minutes (doses >20 mcg/kg/min risk vasoconstriction and arrhythmias) 1
Epinephrine: 2-10 mcg/min IV titrated to effect 1
Isoproterenol: 20-60 mcg IV bolus or 1-20 mcg/min infusion (monitor for ischemic chest pain) 1
Important warning: Use beta-agonists cautiously in patients at risk for myocardial ischemia due to increased myocardial oxygen consumption. 1
Specific Antidotes for Drug-Induced Bradycardia:
Calcium channel blocker overdose: 10% calcium chloride 1-2 g IV every 10-20 minutes 1
Beta-blocker or calcium channel blocker overdose: Glucagon 3-10 mg IV bolus followed by 3-5 mg/h infusion 1
Digoxin toxicity: Digoxin-specific antibody fragments (one vial binds ~0.5 mg digoxin) 1
Pacing Strategies
Transcutaneous Pacing (TCP)
Apply transcutaneous pacing immediately if atropine is ineffective or contraindicated, or if the patient has high-risk features suggesting progression to complete heart block. 1
High-risk rhythms requiring immediate TCP consideration: 1
- Mobitz type II second-degree AV block
- Third-degree AV block with wide QRS escape rhythm
- New bifascicular block (RBBB with left anterior or posterior fascicular block, or new LBBB) in setting of acute MI
- Asystolic pauses ≥3 seconds
TCP limitations: Electrical capture occurs in only ~10% of prehospital cases and is associated with significant pain, so it serves as a bridge to transvenous pacing. 1, 3
Transvenous Pacing
Transvenous pacing is indicated for: 1
- Persistent symptomatic bradycardia unresponsive to atropine and TCP
- Mobitz type II second-degree AV block
- Complete heart block with symptomatic bradycardia
- Bilateral bundle branch block or alternating bundle branch block
Important consideration: Delayed permanent pacemaker implantation (≥3 days) is NOT associated with increased adverse events compared to early implantation (≤2 days), but temporary transvenous pacing itself increases complications (19.1% vs 3.4% adverse events). 2
Permanent Pacemaker Indications
Class I (Definite Indications):
Permanent pacemaker is definitively indicated for: 1
Complete heart block (third-degree AV block) with any of the following:
- Symptomatic bradycardia (syncope, heart failure, confusion that clears with pacing)
- Documented asystole ≥3 seconds or escape rate <40 bpm while awake
- Post-AV junction ablation 1
Second-degree AV block (Mobitz type I or II) with symptomatic bradycardia 1
Sinus node dysfunction with documented symptomatic bradycardia (correlation of symptoms with bradycardia required) 1
Persistent advanced second-degree or complete heart block after acute MI with bilateral bundle branch block 1
Class III (Not Indicated):
Do NOT implant permanent pacemaker for: 1
- Asymptomatic bradycardia
- Symptoms clearly documented to occur in the absence of bradycardia
- Symptomatic bradycardia due to non-essential drug therapy (discontinue offending medication first)
- First-degree AV block alone 1
- Asymptomatic Mobitz type I (Wenckebach) with normal hemodynamics 1
Common Pitfalls to Avoid
Do not give atropine doses <0.5 mg as this can paradoxically worsen bradycardia. 1
Do not use atropine in post-heart transplant patients without documented autonomic reinnervation—it will not work and may cause harm. 1
Do not rely on atropine for Mobitz type II or third-degree AV block with wide QRS—these require pacing as the block is infranodal. 1
Do not use temporary transvenous pacing routinely—it significantly increases complications (central line infections, cardiac perforation); transcutaneous pacing is safer as a bridge. 1, 2
In acute MI with bradycardia, use atropine cautiously—excessive tachycardia can extend infarct size and increase risk of ventricular fibrillation. Titrate to minimally effective heart rate (~60 bpm), not maximal heart rate. 1
Weekend hospital admissions are associated with delayed permanent pacemaker placement (median 1-day delay), increased temporary transvenous pacing use, and 2-day longer hospital stays—consider weekend pacemaker implantation for appropriate candidates. 2